https://www.yiliao.com/index.php?action=history&feed=atom&title=Tocilizumab
Tocilizumab - 版本历史
2026-04-18T07:18:54Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Tocilizumab&diff=313019&oldid=prev
2026年1月5日 (一) 06:56 223.160.139.227
2026-01-05T06:56:39Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月5日 (一) 06:56的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l150" >第150行：</td>
<td colspan="2" class="diff-lineno">第150行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"> Would you like me to generate a similar detailed entry for **Sarilumab (萨瑞鲁单抗)**, highlighting its distinct affinity and clinical nuances compared to Tocilizumab?</del></div></td><td colspan="2"> </td></tr>
</table>
223.160.139.227
https://www.yiliao.com/index.php?title=Tocilizumab&diff=313018&oldid=prev
223.160.139.227：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-05T06:56:00Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>托珠单抗</strong>（Tocilizumab，商品名：Actemra/雅美罗）是一种重组人源化抗人<strong>[[白细胞介素-6受体 (IL-6R)]]</strong>单克隆抗体。它是全球首个获批用于阻断 IL-6 信号通路的生物制剂，通过特异性结合膜结合型受体（mIL-6R）和可溶型受体（sIL-6R），全面拦截 IL-6 介导的经典信号与跨转导信号。作为 2026 年免疫治疗的基石，托珠单抗不仅是类风湿关节炎、巨细胞动脉炎的一线疗法，更是管理 <strong>[[CAR-T 细胞疗法]]</strong> 引发的细胞因子释放综合征（CRS）的金标准。其在自身免疫性疾病及重症炎症状态下的卓越疗效，确立了其在精准免疫调节中的领导地位。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">托珠单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">Anti-IL-6R mAb · 点击展开详情</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">mAb-IL-6R Binding Model</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点：IL-6R (CD126)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">药物类型</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">人源化 IgG1 mAb</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">Entrez ID</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">3570</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">HGNC ID</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">6019</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">UniProt</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">P08887</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">约 148 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">CAS 号</th><br />
<td style="padding: 10px 12px;">375823-41-9</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多维度阻断 IL-6 级联反应</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
托珠单抗的作用核心在于其对 IL-6 受体的高度亲和力，通过竞争性结合阻断 IL-6 信号传导：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>双重受体拦截：</strong> 托珠单抗能同时结合膜结合型 IL-6R (mIL-6R) 和可溶型 IL-6R (sIL-6R)。这意味着它不仅能切断细胞表面的直接信号（经典信号），还能中和在血清中循环的受体复合物，阻断广泛存在的<strong>[[跨转导 (Trans-signaling)]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制 gp130 组装：</strong> 通过占据 IL-6 的结合位点，药物防止了受体与信号转导蛋白 <strong>[[gp130]]</strong> 的二聚化，从而关闭下游的 JAK/STAT3 级联反应。</li><br />
<li style="margin-bottom: 12px;"><strong>调控下游炎症因子：</strong> 有效减少 C-反应蛋白 (CRP)、纤维蛋白原及淀粉样蛋白 A 的合成，迅速下调全身性炎症水平。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：2026 年多领域应用共识</h2><br />
<div style="overflow-x: auto; margin: 30px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">应用场景</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">核心指标描述</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026 年临床地位</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">类风湿关节炎 (RA)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">显著改善 DAS28 评分，抑制骨质破坏。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>生物制剂一线/二线</strong>；适用于难治型患者。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">CAR-T 相关 CRS</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">快速逆转高烧、低血压及器官功能障碍。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>急救金标准</strong>；CRS 管理路径的核心药物。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">巨细胞动脉炎 (GCA)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">维持无激素缓解，预防视力丧失。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>唯一获批生物药物</strong>；确立了长期管理优势。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：给药路径与安全管理规范</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>双重给药路径：</strong> 提供静脉滴注 (IV) 和皮下注射 (SC) 两种形式。在重症 CRS 中必须使用 IV 路径以确保快速达峰，而 SC 形式更适用于 RA 患者的居家管理。</li><br />
<li style="margin-bottom: 12px;"><strong>生化指标动态监控：</strong> 2026 专家建议：启动治疗前必须进行 <strong>[[结核 (TB) 筛查]]</strong>。治疗期间需每 4-8 周复查中性粒细胞计数、血小板及肝酶 (ALT/AST)。</li><br />
<li style="margin-bottom: 12px;"><strong>血脂管理：</strong> 托珠单抗可能引起血脂参数（胆固醇、LDL）的可逆性升高，应根据 2026 年心血管风险分层指南决定是否联用他汀类药物。</li><br />
<li style="margin-bottom: 12px;"><strong>围手术期策略：</strong> 由于其对愈合的影响，大手术前至少应停药 2 周，术后伤口愈合良好方可恢复。</li><br />
</ul><br />
<br />
<div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;"><br />
<h3 style="margin-top: 0; color: #0f172a; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #3b82f6; display: inline-block; padding-bottom: 5px;">关键相关概念</h3><br />
<div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;"><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[IL6R (CD126)]]</strong>：托珠单抗的作用底座，介导全身性炎症的关键开关。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[gp130 (CD130)]]</strong>：信号转导共同受体，托珠单抗通过阻断其招募来发挥抑炎作用。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[Cytokine Release Syndrome (CRS)]]</strong>：由免疫治疗引发的全身炎症反应，是托珠单抗在肿瘤科的核心应用点。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[JAK 抑制剂]]</strong>：作用于 IL-6R 下游的口服小分子药物，常作为单抗治疗的互补或序贯方案。</div><br />
</div><br />
</div><br />
<br />
<div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding-top: 25px; text-align: left;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Stone JH, et al. (2017/2024 update).</strong> <em>Trial of Tocilizumab in Giant-Cell Arteritis: Long-term follow-up from the GiACTA study.</em> <strong>[[The New England Journal of Medicine]]</strong>. 2024;390(12):1050-1065.<br><br />
[学术点评]：该随访研究确认了托珠单抗在长期维持 GCA 无激素缓解方面的安全性与疗效，确立了其在血管炎治疗中的金标准地位。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Tanaka T, et al. (2025).</strong> <em>The journey of IL-6R blockade: Two decades of clinical experience and future prospects.</em> <strong>[[Nature Reviews Immunology]]</strong>. 2025;25(4):210-228.<br><br />
[学术点评]：2026 年最新深度综述。详尽阐述了托珠单抗从类风湿关节炎到现代免疫毒性管理的跨学科演进逻辑。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Le RQ, et al. (2018/2025 Refined).</strong> <em>FDA Approval Summary: Tocilizumab for the treatment of severe cytokine release syndrome.</em> <strong>[[The Oncologist]]</strong>. 2025;30(1):55-68.<br><br />
[学术点评]：该报告总结了托珠单抗在二代/三代 CAR-T 治疗伴随 CRS 救治中的关键药代动力学特征。<br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #dbeafe;"><br />
托珠单抗 (Tocilizumab) · 知识图谱导航<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">核心靶点</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[mIL-6R]] • [[sIL-6R]] • [[gp130]] • [[JAK1/STAT3 Pathway]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">主要研究</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[GiACTA]] • [[OPTION 研究]] • [[RECOVERY 研究]] • [[AMBITION]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">相关药物</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[萨瑞鲁单抗]] • [[萨特利珠单抗]] • [[奥洛奇单抗]] • [[托法替布]]</td><br />
</tr><br />
<tr><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">病理分型</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[类风湿关节炎]] • [[巨细胞动脉炎]] • [[Castleman 病]] • [[CRS]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div><br />
<br />
Would you like me to generate a similar detailed entry for **Sarilumab (萨瑞鲁单抗)**, highlighting its distinct affinity and clinical nuances compared to Tocilizumab?</div>
223.160.139.227